Jackson Creek Investment Advisors LLC Makes New $1.43 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC)

Jackson Creek Investment Advisors LLC bought a new position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 15,498 shares of the biotechnology company's stock, valued at approximately $1,430,000. Blueprint Medicines makes up 0.5% of Jackson Creek Investment Advisors LLC's holdings, making the stock its 17th biggest position.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Compass Wealth Management LLC purchased a new stake in shares of Blueprint Medicines during the fourth quarter worth $69,000. PNC Financial Services Group Inc. increased its holdings in Blueprint Medicines by 63.4% during the 3rd quarter. PNC Financial Services Group Inc. now owns 848 shares of the biotechnology company's stock worth $43,000 after purchasing an additional 329 shares during the period. Van ECK Associates Corp raised its position in Blueprint Medicines by 28.4% in the 4th quarter. Van ECK Associates Corp now owns 872 shares of the biotechnology company's stock valued at $80,000 after purchasing an additional 193 shares in the last quarter. Cutler Group LLC CA boosted its stake in shares of Blueprint Medicines by 1,685.7% in the 3rd quarter. Cutler Group LLC CA now owns 1,000 shares of the biotechnology company's stock valued at $50,000 after buying an additional 944 shares during the period. Finally, China Universal Asset Management Co. Ltd. grew its position in shares of Blueprint Medicines by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,550 shares of the biotechnology company's stock worth $78,000 after buying an additional 757 shares in the last quarter.

Blueprint Medicines Stock Performance

Shares of BPMC stock traded down $1.76 during trading hours on Tuesday, hitting $91.34. The stock had a trading volume of 529,234 shares, compared to its average volume of 759,405. The stock's 50 day moving average is $90.85 and its 200 day moving average is $79.52. The firm has a market capitalization of $5.59 billion, a PE ratio of -10.93 and a beta of 0.63. Blueprint Medicines Co. has a twelve month low of $43.89 and a twelve month high of $101.00. The company has a debt-to-equity ratio of 1.60, a current ratio of 3.76 and a quick ratio of 3.66.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last issued its quarterly earnings data on Thursday, February 15th. The biotechnology company reported ($1.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.04) by $0.22. Blueprint Medicines had a negative net margin of 203.30% and a negative return on equity of 191.56%. The company had revenue of $71.96 million for the quarter, compared to the consensus estimate of $67.34 million. During the same period last year, the firm posted ($2.65) EPS. Blueprint Medicines's revenue for the quarter was up 85.5% on a year-over-year basis. As a group, research analysts forecast that Blueprint Medicines Co. will post -5.41 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Wedbush reaffirmed an "outperform" rating and issued a $110.00 target price on shares of Blueprint Medicines in a report on Friday. Needham & Company LLC restated a "buy" rating and issued a $97.00 price objective on shares of Blueprint Medicines in a report on Friday. JMP Securities reaffirmed a "market outperform" rating and set a $114.00 price objective on shares of Blueprint Medicines in a research report on Wednesday, April 10th. HC Wainwright reissued a "buy" rating and issued a $125.00 target price on shares of Blueprint Medicines in a report on Friday. Finally, Stifel Nicolaus lifted their price target on Blueprint Medicines from $120.00 to $130.00 and gave the stock a "buy" rating in a report on Friday. Four research analysts have rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Blueprint Medicines currently has an average rating of "Hold" and a consensus price target of $91.57.

Insider Activity at Blueprint Medicines

In other news, insider Christopher K. Murray sold 5,000 shares of the company's stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $100.00, for a total transaction of $500,000.00. Following the completion of the sale, the insider now owns 24,495 shares in the company, valued at $2,449,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Christopher K. Murray sold 621 shares of the firm's stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $93.65, for a total value of $58,156.65. Following the completion of the sale, the insider now owns 36,374 shares in the company, valued at $3,406,425.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Christopher K. Murray sold 5,000 shares of Blueprint Medicines stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $100.00, for a total value of $500,000.00. Following the completion of the sale, the insider now directly owns 24,495 shares in the company, valued at approximately $2,449,500. The disclosure for this sale can be found here. Insiders have sold 92,289 shares of company stock worth $8,314,163 in the last quarter. Company insiders own 3.88% of the company's stock.

Blueprint Medicines Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.